Our pipeline
Shared roots.Expanding directions.
Senotherapeutic programs across oncology, fibrosis, and neurodegeneration.
ProgramIndication
DiscoveryPreclinicalPhase 1Phase 2Phase 3
Oncology
NL-101
Solid tumorsBladder, breast, melanoma, lung, and renal cancers
Preclinical evaluationPhase 3
Fibrosis
NL-102
Liver fibrosisProgressive fibrotic liver disease
DiscoveryPhase 3
NL-103
Lung fibrosisFibrotic interstitial lung disease
DiscoveryPhase 3
NL-104
Kidney fibrosisChronic fibrotic kidney disease
DiscoveryPhase 3
Neurodegeneration
NL-105
Neurodegenerative diseaseAge-related neuroinflammation and decline
DiscoveryPhase 3
Bars show the current stage of each program. Phase 1 to Phase 3 are the clinical stages a program must complete before regulatory review; no Nebula Longevity program has entered clinical testing.
Separate from our drug pipeline
Healthy-aging nutraceuticals
Some natural-product candidates may be better suited to supporting healthy aging than to treating disease. We are evaluating whether selected candidates could be developed as nutraceuticals or dietary supplements.
How this path differs
- It follows food and supplement standards, not the drug approval pathway.
- It runs independently of the NL-numbered therapeutic programs.
- No supplement product is currently available.
Statements about potential supplement products have not been evaluated by the U.S. Food and Drug Administration. Such products would not be intended to diagnose, treat, cure, or prevent any disease.
Work with us
Contact us